New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics

NEW YORK, June 13, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), The Cooper Companies, Inc. (NYSE: COO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Apricus Biosciences Inc. (NASDAQ: APRI), and NewLink Genetics Corp. (NASDAQ: NLNK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Boston Scientific Corporation Research Report

On June 3, 2013, Boston Scientific Corporation (Boston Scientific) announced that it will provide a research and education grant of more than $1 million to the Pelvic Floor Disorders Networks (PFDN) for the SUPeR clinical trial. The SUPeR study will evaluate the treatment outcomes of two different surgical options for women with uterine prolapse, a form of pelvic organ prolapse. The study will enroll 180 women who are considering surgery for their uterine prolapse and do not plan to have any more children. They will be randomly assigned to either a uterine-preserving transvaginal mesh repair using the Boston Scientific Uphold LITE Vaginal Support System or traditional surgery that will include a vaginal hysterectomy. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5649_BSX]

--

The Cooper Companies, Inc. Research Report

On June 6, 2013, The Cooper Companies, Inc. (Cooper) announced its financial results for Q2 FY 2013 (period ended April 30, 2013). Revenue increased 11.4% YoY to $384 million. GAAP EPS increased 35.7% YoY to $1.52. Commenting on the results, Robert S. Weiss, Cooper's President and Chief Executive Officer, said, "I am enthused by our performance as we continue executing on our long-range strategies that lead to gaining market share and improving our operating margin." For full-year FY 2013, the Company expects revenue in the range of $1,575 million to $1,605 million, and GAAP EPS in the range of $6.42 to $6.52. The Full Research Report on The Cooper Companies, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/9fd9_COO]

--

Arena Pharmaceuticals, Inc. Research Report

On June 7, 2013, Arena Pharmaceuticals, Inc. (Arena Pharmaceuticals) reported the launch of BELVIQ in the United States. The product will be available to patients by prescription in US pharmacies beginning June 11, 2013. Eisai Inc. (Eisai) is responsible for the marketing and distribution of BELVIQ under its agreement with Arena Pharmaceuticals GmBH, a wholly-owned subsidiary of Arena Pharmaceuticals. The Company reported that it manufactures BELVIQ at its manufacturing facility in Switzerland and sells the finished commercial product to Eisai for a purchase price starting at 31.5% of Eisai's annual net product sales. The purchase price increases on a tiered basis of up to 36.5% on the portion of annual net product sales exceeding $750 million. In relation with the US launch of BELVIQ, Arena has received $65 million in milestones from Eisai. Further, Eisai has submitted a marketing authorization application for BELVIQ in Mexico and plans to submit applications for the approval of BELVIQ in Canada and Brazil in 2013. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/6991_ARNA]

--

Apricus Biosciences Inc. Research Report

On June 10, 2013, Apricus Biosciences Inc. (Apricus Bio) announced that its marketing application for Vitaros, indicated for the treatment of patients with erectile dysfunction (ED), has been approved through the European Decentralized Procedure (DCP). Commenting on the approval, Richard Pascoe, Chief Executive Officer of Apricus Bio, said, "With its rapid onset of action and unique topical delivery, we believe that Vitaros will capture a significant share of the approximately $1 billion PDE-5 inhibitor market in Europe once it is launched by our commercial partners." Under the DCP, the Company filed its application for marketing approval designating Netherlands as the Reference Member State (RMS) on behalf of nine other European Concerned Member States (CMS) participating in the procedure. The CMS include France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium, and Luxembourg. Apricus Bio will continue to work independently as well as with its commercialization partners, Sandoz, Takeda, and Bracco for the next step of obtaining national phase approvals in order to make Vitaros ready to launch in each of the included territories across Europe. The Full Research Report on Apricus Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2aca_APRI]

--

NewLink Genetics Corp. Research Report

On June 3, 2013, NewLink Genetics Corporation (NewLink Genetics) announced results from a Phase 2 clinical study with its drug candidate algenpantucel-L. The study evaluated algenpantucel-L plus standard-of-care adjuvant therapy (gemcitabine and 5-FU-modulated radiation therapy) in 69 patients with resected pancreatic cancer. The study defined disease-free survival at one year as its primary endpoint, and overall survival, safety, and immunological correlative analysis as the secondary endpoints. The data showed that one year disease-free survival was 62%, while overall survival was 86%. Specifically, the data showed median overall survival was 42 months in patients with elevated levels of anti-mesothelin antibodies versus 20 months in patients without elevated levels. Moreover, the subset of patients that showed increases in two or more of the aforementioned biomarkers had median overall survival greater than 42 months (median overall survival not reached for this subset of patients). The Full Research Report on NewLink Genetics Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/c29b_NLNK]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquires, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports